Sotera Health reports Q4 adjusted EPS 26c, consensus 26c

Reports Q4 revenue $310.239M, consensus $302.15M. “Today I am pleased to announce another year of top- and bottom-line growth,” said Chairman and Chief Executive Officer, Michael Petras, Jr. “Throughout 2023, the Sotera Health team demonstrated resilience, adaptability and an unwavering commitment to the Company’s core values in the face of continued macro-economic pressures. During the year, Sterigenics completed four capacity expansions, the Nordion team successfully navigated the complex Cobalt-60 supply chain, and Nelson Labs continued to provide our customers with world-class lab testing services and expert advisory support. We remain focused on our mission of Safeguarding Global Health and are excited for continued growth in 2024.”